Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page now presents new guidance/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and a 'No longer looking for participants' notice. The Intervention/Treatment heading has been updated and the older 'Intervention / Treatment' label removed, alongside a new revision indicator 'Revision: v3.6.0' replacing the previous version.SummaryDifference0.4%

- Check10 days agoChange DetectedThe page's revision tag has been updated from v3.5.4 to v3.5.5, representing a new build of the ClinicalTrials.gov page. It indicates an update to the site software rather than changes to the study information presented on the page.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page adds a new site revision tag for v3.5.4 and removes the previous v3.5.3 label, signaling a small platform update in the release notes area rather than changes to the study information.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page now displays a new revision tag (v3.5.3), replacing the previous v3.5.2, indicating a release update to the page's content management without altering study data. No study details or eligibility criteria appear to be changed.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check67 days agoChange DetectedThe study page now shows 'Results Submitted' instead of 'No Results Posted'.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.